Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

作者：James Chih‐Hsin Yang, Baohui Han, Emmanuel de la Mora Jimenez, Jong-Seok Lee, P. Koralewski, Nuri Karadurmuş, Shunichi Sugawara, Lorenzo Livi, Naveen S. Basappa, Xavier Quantin, Julia Dudnik, Diego Moran Ortiz, Tarek Mekhail, Chinyere E. Okpara, Corina E. Dutcus, Zachary Zimmer, Ayman Samkari, Niyati Bhagwati, Tibor Csőszi · 发表于：Journal of Thoracic Oncology · 年份：2023 · DOI：10.1016/j.jtho.2023.12.023 · 被引用次数：55 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment